Anti-viral Drugs Market (2021-2025) | Gilead Sciences Continues to Lead Anti-viral Drugs Market, Says Fairfield Market Research
Get Sample of this Report (Including Full TOC, List of Tables & Figures): https://www.fairfieldmarketresearch.com/report/anti-viral-drugs-market/
Different Strains of Hepatitis Lead to Further Complications in Emerging Economies
As per WHO data, Hepatitis B and C affect a large number of people and are especially problematic as they can lead to further complications such as hepatocellular carcinoma and cirrhosis. Hepatitis B and C, along with hepatitis A and E, typically occur in developing regions with sub-par hygiene standards. Anti-viral drugs have already proven their efficacy against hepatitis C, and this can play a leading role in lowering the mortality rate of liver cirrhosis. Along with hepatitis, annual epidemics of seasonal influenza can lead to severe illness and respiratory failure. In 2021, millions of people are living with both types of herpes simplex virus – HSV-1 and HSV-2. Thus, there is immense scope for key stakeholders in the anti-viral drugs market.
A Spike in Demand Has Led to Shortages of COVID-19 Anti-Viral Drugs Such as Remdisivir
The COVID-19 pandemic has brought the global economy to a standstill and we are emerging from lockdowns on a step-by-step basis. Until vaccine shortages are effectively addressed, COVID-19 is a challenge that will loom on the horizon for some time. There has been an increased rate of anti-viral drugs being launched in the anti-viral drugs market to tackle the novel coronavirus with a prominent one being Remsdesivir, In terms of genome sequencing, COVID-19 has exhibited notable similarities to both MERS and SARS. The large number of clinical trials already underway or in the announcement phase are predicted to boost the anti-viral drugs market for the forecast period assessed.
Top Ten Companies Almost Entirely Control the Anti-viral Drugs Market
The anti-viral drugs market is anticipated to record a modest rate of growth for the period 2020-2025. It is oligopolistic as the top 10 companies hold the lion’s share in the anti-viral drugs market. Mavyret’s low treatment course lasting two months has gained considerable popularity in the anti-viral drugs market. The other leading companies in the anti-viral drugs market are GlaxoSmithKline, AbbVie, Johnson & Johnson, Sino Biopharmaceutical, Merck & Co, Bristol-Myers Squibb, Aurobindo Pharma, Arbutus Biopharma, and Roche.
Have Query? Ask Experts: firstname.lastname@example.org
Gilead Sciences Pioneer in the HIV Segment of the Anti-viral Drug Market
In 2021, Gilead Sciences is a pioneer in anti-viral drugs and should retain leadership for the assessment period. Nonetheless, robust competition means that it should lose market share in the global anti-viral drugs market – mainly due to decreased sales of HCV. Gilead Sciences is particularly strong in the HIV drug segment with its Biktarvy offering. Along with Biktarvy, Triumeq and Tivicay by GSK, and Genvoya by Torii Pharmaceutical are predicted to be the highest selling products in the anti-viral drugs market until 2025.
Browse Our Latest Reports: https://www.fairfieldmarketresearch.com/shop/
Fairfield Market Research
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Follow us on LinkedIn: https://bit.ly/3voYIm9
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-viral Drugs Market (2021-2025) | Gilead Sciences Continues to Lead Anti-viral Drugs Market, Says Fairfield Market Research here
News-ID: 2300412 • Views: 343
More Releases from Fairfield Market Research
Double-digit Growth on the Anvil in Asia-Pacific Yacht Charter Market, States Fa …
The global yacht charter market is driven by an upsurge in leisure activities as consumers across demographics discover the pleasure of yachting to exotic locations. Charter yachts are immensely popular as they rival the best that luxury hotels have to offer with the added advantage of complete seclusion as any tourists can travel to a waterbody of their choice. Tourists can visit several locations in a single trip and avoid
Microbial Fuel Cell (MFC) Market Will be Worth US $15.59 Mn by 2025, Registering …
The global microbial fuel cell (MFC) market is expected to cross the growth threshold required for competitors to make lucrative gains. The total worth of the global microbial fuel cell (MFC) market is expected to supplant US $15 Mn by the end of 2025, growing at a stupendous CAGR of 9.8% during the period between 2021 and 2025. The wide spectrum of applications pertaining to microbial fuel cells is the
Global Graphite Market Poised for a Robust 8.5% CAGR for by 2025; Steelmaking, a …
One of the most desirable materials among those active in the next-generation energy sector, graphite represents a rapidly progressing, multi-billion-dollar market at a global level. Majorly fuelled by the advent of renewable energy sources, and innovations in green energy technologies, Fairfield Market Research expects the global graphite market to see a robust growth outlook during 2021 – 2025. A new report by the company forecasts a strong 8.5% CAGR for
Global Toothpaste Tablet Market to Remain Afloat as Green Practices of Personal …
Sale of toothpaste tablets is gaining momentum as a large section of the global population gravitates towards following staunch standards of personal hygiene. The global value of the toothpaste tablet market is estimated to touch US$152.3 Mn by 2026, growing at a robust CAGR of 6.8% during the period between 2021 and 2026. The past decade has witnessed a heavy uptick in advertising budgets of personal care products. This has
More Releases for Hepatitis
Hepatitis E Therapeutics Pipeline Analysis 2018
Hepatitis E is a liver disease caused by infection due to a virus known as hepatitis E virus (HEV). This disease can cause swelling in liver. Some of the common symptoms are mild fever, feeling of tiredness, feeling sick to stomach, and belly pain. Download the sample report at: https://www.pharmaproff.com/request-sample/1029 The World Health Organization (WHO) estimates released in 2018 stated that, every year, an estimated 20 million HEV infections worldwide, leading to
Hepatitis Drugs Market Opportunity Assessment Study
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in
Global Hepatitis A Vaccine Sales Market Report
In this report, the global Hepatitis A Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis A Vaccine for these regions, from 2013
Hepatitis B Vaccines Market Growth Analysis 2021
Hepatitis B refers to an infectious disease that is caused by hepatitis B virus. Symptoms of this disease are not visible in initial stages and develop after few weeks only. Hepatitis B virus is transmitted by exposure to infectious blood or body fluids of an infected person. This disease may even occur from the birth. Hepatitis B may be caused by blood transfusions, healthcare setting, sharing razors and dialysis. Hepatitis
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Global Hepatitis C Drug Sales Market 2017
In this report, the Global Hepatitis C Drug Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis C Drug for these regions, from 2012